introduction and aims: omeprazole is a gastric parietal cells proton pump inhibitor that is also active against h. pylori in vitro. this study was designed to examine the neutralization of h. pylori cytotoxicity on vero cells by omeprazole micronized in strains isolated from gastritis, ulcer, cancer and barrett's ulcer, to determine whether omeprazole can inhibit vacuolation of the vero cells i...

Aims: To study force degradation of aspirin and omeprazole simultaneously by RP-HPLC method
 Study design: method was used to measure % degradation.
 Place Duration Study: carried out at center excellence, G.I.D.C., vapi-396195, Gujarat, India between June 2019 march 2020.
 Methodology: A simultaneously. The drugs were subjected various conditions like hydrolysis acid base, Oxida...

BACKGROUND Generic omeprazole contains the same active ingredient as original omeprazole and require verification of the bioequivalence with original omeprazole. However, very few clinical studies have been reported. AIMS A prospective, randomised, open-label, crossover study to compare acid-suppressive effect of generic omeprazole with that of original omeprazole. SUBJECTS Seven healthy He...

 ABSTRACT Background: Aspirin even at low dose ( 100 mg) can increase the risk of upper gastrointestinal bleeding. It is usual to use low dose aspirin for cardiovascular prophylaxis. We hypothesized that Helicobacter pylori eradication is as effective as omeprazole maintenance therapy for secondary prevention of bleeding in those who take low dose aspirin and are positive for Helicobacter pylor...

Previous studies have shown that the proton pump inhibitor omeprazole has antimalarial activity in vitro. The interactions of omeprazole with commonly used antimalarial drugs were assessed in vitro. Omeprazole and quinine combinations were synergistic; however, chloroquine and omeprazole combinations were antagonistic. Artemisinin drugs had additive antimalarial activities with omeprazole.

Proton pump inhibitors (PPIs) are widely used drugs that may increase the cardiovascular risk by mechanisms not entirely known. While PPIs increase asymmetric dimethylarginine (ADMA) levels and inhibit nitric oxide production, it is unknown whether impaired vascular redox biology resulting of increased xanthine oxidoreductase (XOR) activity mediates PPIs-induced endothelial dysfunction (ED). We...

As a direct-acting inhibitor of CYP2C19 in vitro, lansoprazole is more potent than omeprazole and other proton pump inhibitors (PPIs), but lansoprazole does not cause clinically significant inhibition of CYP2C19 whereas omeprazole does. To investigate this apparent paradox, we evaluated omeprazole, esomeprazole, R-omeprazole, lansoprazole, and pantoprazole for their ability to function as direc...

Background: Omeprazole is metabolized predominantly by CYP2C19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. These variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. The aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random Iranian population. Met...

This study demonstrates the stereoselective metabolism of the optical isomers of omeprazole in human liver microsomes. The intrinsic clearance (CL(int)) of the formation of the hydroxy metabolite from S-omeprazole was 10-fold lower than that from R-omeprazole. However, the CL(int) value for the sulfone and 5-O-desmethyl metabolites from S-omeprazole was higher than that from R-omeprazole. The s...

Omeprazole and E3810 were found to inhibit gastric H+,K(+)-ATPase following different biochemical mechanisms. Effects of the specific binding of the inhibitors on the conformational state of the enzyme were studied by measuring the fluorescence of the enzyme labeled with fluorescein 5'-isothiocyanate. The absolute fluorescence level of the omeprazole-bound enzyme was lower than that of the cont...